Multi-center non-randomized open trial to evaluate the efficacy of azacitidine followed by allo-HSCT for TP53(+) MDS.
Phase of Trial: Phase II
Latest Information Update: 20 Jun 2019
Price : $35 *
At a glance
- Drugs Azacitidine (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms REPTAT trial
- 17 Oct 2017 Status changed from not yet recruiting to recruiting.
- 07 Oct 2017 Planned initiation date changed from 1 Aug 2017 to 5 Oct 2017.
- 22 Jun 2017 New trial record